Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2020
Subject: Item 8.01 Other Events regarding the U.S. BLA for the Lucentis (ranibizumab) biosimilar candidate licensed from Bioeq AG.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Status
- BLA Withdrawal: Bioeq AG has decided to withdraw its Biologic Licensing Application (BLA) for the Lucentis biosimilar candidate.
- Cause: The FDA requested additional manufacturing data regarding a piece of processing equipment that was moved to a different location within the same manufacturing site after qualification batches were produced.
- Timeline Impact: The Company estimates it will take approximately four months to generate the required data.
- Next Steps: Bioeq will provide the requested data and resubmit the application, which is expected to delay the approval timeline.
Outlook, Risks, and Management Commentary
Management anticipates that the withdrawal and subsequent resubmission of the BLA will delay the approval of the Lucentis biosimilar candidate. The primary risk identified is the regulatory delay caused by the need to generate additional manufacturing data to satisfy FDA requirements regarding equipment location changes.
Key Facts for Investor Verification
- Verify the specific timeline for the resubmission of the BLA following the four-month data generation period.
- Monitor FDA communications regarding the sufficiency of the additional manufacturing data.
- Assess the potential impact of the approval delay on the Company's projected revenue timeline for the ranibizumab biosimilar.
- Confirm if there are any other regulatory inquiries related to the manufacturing site or equipment.